A Bitter Battle Over the 鈥極rphan Drug鈥 Program Leaves Patients鈥 Pocketbooks at Risk
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.